Mossoff Policy Memo for Hudson Institute Calls for Transparency from I-MAK on Data Used in Drug Pricing Debate

“There may be explanations for such repeated, vast discrepancies between the total numbers of patents and exclusivity periods reported by I-MAK and the official data on the patents covering these drugs that are found in governmental sources such as the FDA’s Orange Book or court opinions. Still, these are substantial discrepancies in total numbers of patents.” – Mossoff Policy Memo Policy Memo published by the Hudson Institute and authored by Professor Adam Mossoff of the Antonin Scalia Law School at George Mason University has charged that some of the key data relied upon in the heated debate over the effects of pharmaceutical patents on drug pricing and access may be faulty.

The memo, titled “Unreliable Data Have Infected the Policy Debates Over Drug Patents,” specifically targets the Initiative for Medicines, Access & Knowledge (I-MAK), an advocacy organization that has become a “principal, go-to source” for data on the number of patents and patent applications covering pharmaceutical innovations. I-MAK’s mandate is to “build a more just and equitable medicine system for all,” a goal it believes requires “restor[ing] integrity to the U.S. patent system” by updating it to bar certain industry practices, according to its website and press releases.

I-MAK’s view is that the U.S. patent system creates patent monopolies that lead to the practice of “evergreening”, in which innovator pharmaceutical companies extend their rights beyond the original patent terms, preventing competition from generics, which in turn causes drug prices to remain high. According to Mossoff’s paper, I-MAK was the first policy organization to file a petition with the Patent Trial and Appeal Board (PTAB) to cancel a pharmaceutical patent on a Hepatitis C drug.

As part of its mission, I-MAK has developed a database of patents covering key drugs. Reports like Overpatented, Overpriced and America’s Bestselling Drugs of 2019 are often cited by academics, including in law journals, policymakers and in congressional hearings. To be sure, I-MAK has become the authoritative source for information on patents in this space; the problem, says Mossoff, is that there is a vast discrepancy between the I-MAK and government data that cannot be explained because I-MAK does not disclose or explain its underlying dataset, making its numbers “impossible to confirm.”

Mossoff’s examples of this discrepancy include: I-MAK’s assertion in Overpatented, Overpriced that Pfizer’s treatment for nerve damage, Lyrica, is covered by 68 patents when the Food and Drug Administration’s (FDA’s) Orange Book lists only four (one of which is a reissue); that Bristol Myers Squibb’s popular drug to treat blood clots, Eliquis, is covered by 27 issued patents and 48 applications when the Orange Book lists only three; and that Janssen Pharmaceuticals’ blood clot treatment, Xarelto, is covered by 30 issued patents and 49 pending applications compared with the Orange Book’s six. Mossoff also notes discrepancies year over year in I-MAK’s numbers that cannot be explained, and that the organization cites exclusivity periods far into the future despite generics having already entered the market in some cases.

The methodology used in the Overpatented, Overpriced report is available here, on pages 12-13.

I-MAK Co-Founder and Co-Executive Director Tahir Amin, who has 25 years’ experience as a patent attorney, spoke with IPWatchdog in 2019 and distinguished between the Orange Book patents covering Gilead’s HIV drug, Truvada, and other patents on antiviral combinations that would still block generic access in his view.

However, Mossoff argues that, without the specific datasets and coding variables I-MAK uses to reach its conclusions, there are many open questions remaining.

The paper concludes:

Ultimately, there may be explanations for such repeated, vast discrepancies between the total numbers of patents and exclusivity periods reported by I-MAK and the official data on the patents covering these drugs that are found in governmental sources such as the FDA’s Orange Book or court opinions. Still, these are substantial discrepancies in total numbers of patents—the differences are on the scale of an order of magnitude in some cases. In light of these factual discrepancies, I-MAK’s empirical claims in the “evergreening” policy debate are an unreliable foundation for policymaking.

Thus, whatever the explanation, says Mossoff, the I-MAK data should no longer be relied upon until these questions are resolved.

IPWatchdog reached out to I-MAK for comment but had not received a response as of the time of writing.

Image Source: Deposit Photos
Author: lightsource
Image ID: 29660399 


Warning & Disclaimer: The pages, articles and comments on do not constitute legal advice, nor do they create any attorney-client relationship. The articles published express the personal opinion and views of the author as of the time of publication and should not be attributed to the author’s employer, clients or the sponsors of

Join the Discussion

4 comments so far.

  • [Avatar for xtian]
    January 24, 2022 09:33 am

    The Orange book (OB) is a repository of patents submitted by the Brand asserting that the patents listed there in cover the branded product. The Brand, by statute, shall list its patents. When a generic company files its ANDA (small molecule), it is a statutory act of infringement. The Brand sues the generic even though no generic product is yet on the market. The generic must certify whether those OB patents are invalid or not infringed. Hatch-Waxman Act clearly set forth those rules. If a patent is not listed, the branded company may be precluded from suing the generic for infringement until the generic product is actually approved and on the market. (At which point the market is now ‘genericized,’ and it is near impossible to remove that generic product from the market.) There is every incentive for Branded companies to list all patents in the OB consistent with the HW Act.

  • [Avatar for Peter Kramer]
    Peter Kramer
    January 23, 2022 07:45 pm

    I seriously doubt the Orange Book compiles a list of patents with any claims the scope of which includes each particular drug. I don’t think that’s the intent of the Orange Book’s listing of patents for each drug. Thus, the “discrepancy” does not necessarily suggest the differences are due to error or unreliability of the respective sources.

  • [Avatar for Anon]
    January 21, 2022 12:39 pm

    Admittedly off topic to this article, but the lack of comment indicators at this point may be chalked up to a policy decision, as opposed to a continuing “working out the bugs.”

    I recommend revisiting that decision, as interaction on comments is negatively affected with the current setup.

  • [Avatar for Julie Burke]
    Julie Burke
    January 21, 2022 11:51 am

    Thank you, Professor Mossoff, for digging deep into the records to expose information underlying I-MAK’s assertions which is not consistent with the facts. Inaccurate information, if not corrected, has a way of becoming blindly accepted as the truth. The country needs and deserves more accurate underpinnings upon which rational policies can be debated.